PS
Praveen Sadananda Gopan
About Praveen Sadananda Gopan
Praveen Sadananda Gopan has 3 years in corporate governance. Holds Director role. Currently with 3 companies, including Neovexis Pharma Private Limited and Pravaha Hospitals Private Limited. Formerly with 1 company, such as Slynamics Management Consultants Private Limited. Engaged in General Business. Contributes to corporate operations.
Current companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Neovexis Pharma Private Limited
U23104TS2025PTC200917
|
Director | 31 Dec 2025 | 2025 | Active |
Pravaha Hospitals Private Limited
U86100TS2025PTC200729
|
Director | 03 Jul 2025 | 2025 | Active |
Lumiz Management Consultants Limited
U70200TS2024PLC189659
|
Director | 26 Sep 2024 | 2024 | Active |
Previous companies
| Company | Designation | Appointment | Founded | Status |
|---|---|---|---|---|
Slynamics Management Consultants Private Limited
U70200TS2023PTC175063
|
Director | 17 Jul 2023 | 2023 | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Praveen Sadananda Gopan
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Praveen Sadananda Gopan
Praveen Sadananda Gopan has 3 years in corporate governance. Holds Director role. Currently with 3 companies, including Neovexis Pharma Private Limited and Pravaha Hospitals Private Limited. Formerly with 1 company, such as Slynamics Management Consultants Private Limited. Engaged in General Business. Contributes to corporate operations.
Praveen Sadananda Gopan is associated with 3 companies as Director.
Praveen Sadananda Gopan has expertise in General Business.
Praveen Sadananda Gopan has 3 years in corporate governance.